Clinical Research
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 28, 2005; 11(48): 7631-7638
Published online Dec 28, 2005. doi: 10.3748/wjg.v11.i48.7631
Table 2 Patient Characteristics [data given as number (%) or median (range)]
HCV-infection(Group I)HIV-infection(Group II)HCV/HIV-coinfection(Group III)Statistical significance
Number11285121
Sex (Male / female)108 / 473 / 12117 / 4Group I vs II P = 0.009*; group II vs III P = 0.007*
Age (median, range)39 (13 - 77)38 (23 - 70)37 (21 - 62)
Risk factors (%)
Sexual- - -62 (72.9)1 (0.8)Group I vs II and II vs III P < 0.001*
Endemic- - -5 (5.9)- - -Group I vs II P = 0.009*; group II vs III P = 0.011*
I.V. drugs- - -4 (4.7)3 (2.4)Group I vs II P = 0.023*
Blood transfusion- - -1 (1.2)- - -
Hemophilia110 (98.2)- - -115 (95.0)Group I vs II P < 0.001*; group II vs III P < 0.001*
Unknown2 (1.8)13 (15.3)2 (1.7)Group I vs II P < 0.001*; group II vs III P < 0.001*
Aminotransferase activities
ALT U/L (median, range)34.0 (5.2 - 226.0)17.0 (7.0 - 84.0)38.5 (1.0 - 214.0)Group I vs II and II vs III P < 0.001
AST U/L (median, range)19.0 (5.8 - 157.0)12.0 (4.3 - 106.0)26.1 (7.8 - 168.0)Group I vs II P = 0.002; group I vs III P = 0.030;
Group II vs III P < 0.001
GGT U/L (median, range)25.2 (5.2 - 350.9)17.0 (6.2 - 149.0)42.0 (2.9 - 254.6)Group II vs III P < 0.001
HIV-status
CD4 count (median, range)668 (171 - 2 039)/µL350 (5 - 1 142)/µL292.5 (6 - 1 219)/µLGroup I vs II and I vs III P < 0.001
CD8 count (median, range)499 (62 - 1 653)/µL931 (88 - 2 152)/µL804 (39 - 3 056)/µLGroup I vs II and I vs III P < 0.001
HIV load (median, range)- - -300 (<80 - 830 000)725 (<80 - 210,000)
HIV-viremia < 80 copies/mL- - -47 (55.3%)80 (66.1%)
Type of antiretroviral Therapy (%)
Protease inhibitor-based HAART- - -62 (72.9)58 (47.9)Group II vs III P = 0.001
NNRTI-based HAART- - -11 (12.9)25 (20.7)
Total- - -73 (85.9)83 (68.6)Group II vs III P = 0.007
HCV-status
HCV load (copies/mL)8 888 000 (n.d.-126,500,000)- - -13 535 000 (n.d.-178 900 000)Group I vs III P = 0.012
HCV load (IU/mL)1 410 794 (n.d.-20,079,365)- - -2 148 413 (n.d.-28 396 825)
HCV-genotypes (%)
Genotype 170 (62.5)- - -76 (62.8)
Genotype 214 (12.5)- - -11 (9.1)
Genotype 38 (7.1)- - -21 (17.4)Goups I vs III P = 0.028*
Genotype 46 (5.4)- - -5 (4.1)
Multiple genotypes1 (0.9)- - -1 (0.8)
Undeterminded genotype13 (11.6)- - -7 (5.8)
HBV-status (%)
Anti-HBs+ and anti-HBc+52 (46.4)15 (17.6)43 (35.5)
Anti-HBc+ alone10 (8.9)5 (5.9)34 (28.1)Group I vs II P < 0.001; group II vs III P = 0.008
HBs-Ag+1 (0.9)3 (3.5)6 (5.0)Group I vs III P < 0.001; group II vs III P < 0.001*
* Fisher´s exact test; n.d. = not detected.